Clinical trial
Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute…
NCT00002609 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00002609 |
|---|---|
| Title | Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission |
| Official title | PHASE II TRIAL OF POST-REMISSION THERAPY WITH HuM195 AND CYTOTOXIC CHEMOTHERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | lintuzumab, cytarabine, idarubicin |
| Enrollment | 40 |
| Start date | Aug 1, 1994 |
| Primary completion | Feb 1, 2003 |
| Completion | Feb 1, 2003 |
| First posted | Aug 11, 2004 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: